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ABSTRACT 
Objective: To develop a simple and cost effective reverse phase high performance liquid chromatography method for simultaneous estimation of 
Diclofenac and Tolperisone in tablet dosage form.  
Methods: Chromatography was carried out isocratically at 30°C ± 0.5°C on an XDB C-18 column (4.6 x 150mm, 5μ particle size) with a mobile phase 
composed  of  acetonitrile -phosphate  buffer  pH-3.4  (30:70% v/v)  at  a  flow rate  of  1.0  mL/min. Detection  was carried out using a PDA detector 
at 260 nm. Validation parameters were studied as per ICH guidelines.  
Results: The retention times for Diclofenac and Tolperisone are 2.2 min. and 4.7 min. respectively. The linearity range for Diclofenac and 
Tolperisone are 12.5-125µg/mL and 37.5-375 µg/mL respectively. The percentage recoveries of Diclofenac and Tolperisone are 100.75% and 
100.84% respectively. The correlation coefficients for both components are close to 1.  
Conclusion: This method is fast, accurate, precise and sensitive hence it can be employed for routine quality control of tablets containing both drugs 
in industries. 
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INTRODUCTION 
Diclofenac is chemically named as 2-(2-(2,6-dichlorophenylamino) 
phenyl)acetic acid(Figure 2 ). Diclofenac belongs to a class of drugs 
called non-steroidal anti-inflammatory drugs (NSAIDs) that are used 
for the treatment of mild to moderate pain, fever, inflammation such 
as rheumatoid arthritis, gout, pyrophosphate arthropathy, 
osteoarthritis, and ankylosing spondylitis. Diclofenac sodium acts by 
potent cyclo-oxygenase inhibition, reduction of arachidonic acid 
release, and enhancement of arachidonic acid uptake. It thereby 
results in a dual inhibitory effect on both the cyclo-oxygenase and 
lipoxygenase pathways. The recommended dose for most conditions 
is 100-200 mg daily. Diclofenac (DIC) tablets can cause side effects 
like stomach pain, indigestion, heartburn and nausea [1-4]. 
Tolperisone (Figure 2) is chemically named as 2-methyl-1-(4-
methylphenyl)-3-piperidin-1-ylpropan-1-one. Tolperisone is a 
centrally acting muscle relaxant (muscle relaxant acting on spasticity 
by interaction with upper motor neurons), which is also used for the 
treatment of chronic pain. It is mainly used for treating muscle 
spasticities of neurological origin and painful muscle spasms due to 
rheumatologic conditions. Besides being an effective antispastic 
agent, tolperisone (TOL) also has analgesic activity in rodents and in 
humans [5-6]. Various HPLC
 
assay methods are reported in the 
literature for the estimation of Diclofenac [7-13] and Tolperisone 
[14-17] individually and in-combination with other drugs. According 
to literature survey there is no official method for the simultaneous 
estimation of Diclofenac and Tolperisone by RP-HPLC in combined 
tablet dosage forms. In this study, an HPLC method was optimized and 
validated for simultaneous estimation and validation of Diclofenac 














Figure 2: Structure of Tolperisone 
MATERIALS AND METHODS 
Instrumentation: Chromatography was performed with Water’s 
2695 HPLC system provided with Hamilton Syringe, auto sampler 
and 2996 Photodiode array detector. All HPLC systems were 
equipped with a column compartment with temperature 
control and an on-line degasser.  Sample acquisition,  
analysis,  and reporting were performed by Empower2 
(Waters) chromatography software.  
Reagents and chemicals: Pharmaceutically pure sample of 
Diclofenac and Tolperisone were obtained from Spectrum Pharma 
Research Solutions, Hyderabad as gift samples along with their 
analytical reports. Acetonitrile and Methanol of HPLC grade was 
obtained from Merck chemical division, Mumbai and Commercial 
tablets of Diclofenac (50mg), and Tolperisone (150mg); TOLPIDOL-
D was procured from the local drug market. 
Chromatographic condition:  The isocratic mobile phase consisted 
of acetonitrile: phosphate buffer (pH-3.4) in the ratio of 30:70v/v at 
a flow rate of 1.0 ml min-1. XDB C-18 column (4.6 x150mm, 5μ 
particle size) was used as the stationary phase. Although the 
Diclofenac and Tolperisone have different λ max, but considering the 
chromatographic parameter, sensitivity and selectivity of method for 
both drugs, 260 nm was selected as the detection wavelength for 
PDA detector. 
Preparation of standard stock solution: Standard stock  solutions  
were  prepared  by  dissolving 50 mg  of  Diclofenac  drug  and 150 
mg of Tolperisone into a clean and dry 100 ml volumetric flask, 
70ml of diluent was added, sonicated for 5 minutes and volume was 
made up to 100 ml with diluent to get Stock Solution. 
Preparation of Working Standard Solutions: Aliquot of 0.25ml, 
0.5ml, 1.0ml, 1.25ml and 1.5ml and 2.5ml were pipette  out  from  
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stock-A    into  10 ml volumetric flask separately and volume was 
made up to  10ml  with  diluent.  This gives the solutions of 
12.5µg/ml, 25µg/ml, 50µg/ml, 62.5µg/ml, 75µg/ml and 125µg/ml 
respectively for Diclofenac, and 37.5µg/ml, 75µg/ml, 150µg/ml, 
187.5µg/ml, 225µg/ml and 375µg/ml respectively for Tolperisone.  
Sample preparation: Twenty tablets of TOLPIDOL-D containing 
Diclofenac and Tolperisone (50mg & 150mg respectively) were 
weighed and crushed into fine powder. Powder equivalent to weight 
of one tablet was weighed and dissolved in 1 0 0 ml diluent, 
sonicated for 20 min and filtered through PVDF 0.45µ filter. From the 
filtrate, 1 ml was pipetted and transferred into a 10ml volumetric flask and 
the solution was made up to the volume with diluent. 
Method validation: Parameters like system suitability, linearity, 
accuracy, precision, LOD, LOQ, solution stability and robustness 
were estimated as per ICH guidelines. 
RESULTS AND DISCUSSION 
Method development 
Various mobile phase combinations were tried initially to separate 
diclofenac and tolperisone on C18 column. Preliminary experiments 
indicated that using different concentrations of acetonitrile or 
methanol with water was not able to separate the peaks of Diclofenac 
and Tolperisone or to obtain suitable retention and peak shape. In 
order to achieve acceptable peak shapes and perform the separation 
on a suitable run time, various buffer systems were tried 
systematically. The retention time of Diclofenac and Tolperisone 
obtained for different phosphate buffer: acetonitrile ratios (40:60, 
45:55, 50:50, 55:45, 60:40 v/v) indicated that the resolution 
between Diclofenac and Tolperisone increased using higher phosphate 
buffer ratio Thereafter, acetonitrile-phosphate buffer (pH-3.4) 
(30:70 v/v) at a flow rate of 1.0 ml/min. XDB C-18 column (4.6 
x150mm, 5μ particle size) was used as the stationary phase was 
selected to improve resolution, short run time and the tailing of 
both peaks were reduced close to 1.  To analyze both drugs detection 
were tried at various wavelengths from 215nm to 280nm. The 
wavelength at which both Diclofenac and Tolperisone showed 
maximum absorption at 260nm was selected as the detection 
wavelength for PDA detector. The retention time was found to be 
about 2.2 min and 4.7 min for Diclofenac and Tolperisone, respectively. 




















Fig. 3: Representative chromatogram of Diclofenac and Tolperisone 
System Suitability Tests: To ensure the validity of the analytical 
procedure, a system suitability test was established. Data from 
six injections of 10µL of the working   standard   solutions of 
DIC and TOL were used for the evaluation of the system suitability 
parameters like tailing factor, the number of theoretical plates and 
retention time. The results obtained are shown in table-1.  




Linearity: The solutions for linearity were prepared at six 
concentration levels ranging from 25 to 250% of the target 
concentration. Each experiment was performed in triplicate 
according to optimized chromatographic conditions. The peak areas 
of the chromatograms were plotted against the concentrations and 
the correlation coefficients, slopes and Y-intercepts of the calibration 
curve were determined. These results were summarized Figure 4 
and Figure 5. 
 
                  Fig. 4: Calibration Curve for Diclofenac 
PARAMETERS DIC TOL 
No of theoretical plates 5311 4621 
Tailing Factor 1.0 1.6 
Mean Area 1544817 
 
1442973 
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                   Fig. 5: Calibration Curve for Tolperisone 
Accuracy: Recovery studies by the standard addition method were 
performed with a view to justify the accuracy   of   the   proposed   
method.   Previously analyzed samples of DIC and TOL to which 
known amounts of standard DIC and TOL corresponding to 50%, 
100% and 150% of label claim were added. The accuracy expressed 
as the percentage of analyte recovered by the proposed method. 
These results are summarized in table- 2. 









DIC TOL DIC TOL DIC TOL 
50 150 25 75 101.38 101.17 
50 150 25 75 101.33 100.90 
50 150 25 75 102.42 102.92 
50 150 50 150 101.44 100.38 
50 150 50 150 101.57 101.28 
50 150 50 150 100.55 99.32 
50 150 75 225 99.70 100.38 
50 150 75 225 99.12 100.99 
50 150 75 225 99.25 100.23 
MEAN 100.75 100.84 
SD 1.082 0.985 
%RSD 1.07 0.97 
Precision: Precision was determined as repeatability and 
intermediate precision, in accordance with ICH guidelines. The 
intra-day and inter-day precision were determined by analyzing 
the   samples of DIC and TOL. Determinations were performed on the 
same day as well as well as on consequent days. Probability value 
(P) for DIC and TOL at 5% significance level is found to be  0.27and  
0.93 and which are greater than 0.05 and hence no significant 
difference is observed in the precision results carried out on two 
consecutive days and the results are shown in table 3 & 4. 







Repeatability                          
(Day1, Analyst 1) 
1.  1536430 1439107 
2.  1506312 1440512 
3.  1546873 1439593 
4.  1541826 1447510 
5.  1531184 1436482 
6.  1516676 1433833 
Mean 1529884 1439506 
SD 15529.8 4616.7 
%RSD 1.02 0.32 
Intermediate precision 
( Day 2, Analyst 2) 
1. 1543107 1445957 
2. 1524902 1450682 
3. 1552268 1424338 
4. 1548671 1459622 
5. 1548552 1436911 
6. 1520664 1423068 
Mean 1539694 1440096 
SD 13488.9 14670.3 
%RSD 0.88 1.02 









SD= Standard deviation RSD= Relative standard deviation 
Table 4: t- test (statistical test) results for Precision results of 




























Robustness: The change was made in the ratio of mobile phase, 
instead of ACN- Phosphate buffer (30:70 V/V), ACN- Phosphate 
buffer (25:75V/V) & (35:65 V/V) were used as Mobile Phases, 
Column temperature was changed to 25 & 300c, Flow rate was changed 
to 0.9 & 1.1 ml/min. Results of analysis were summarized in table- 5. 











 DIC  TOL DIC  TOL DIC  TOL 




25 2.2 5.5 1.23 1.07 101.56 101.10 
35 2.2 5.4 1.17 1.06 98.68 101.20 
        
Flow 
Rate 
0.9 2.4 6.3 1.19 1.08 98.75 98.61 
1.1 2.0 5.0 1.21 1.07 100.05 101.95 





25:75 2.0 5.3 1.15 1.06 100.26 99.74 
35:65 2.4 5.9 1.18 1.06 100.60 98.92 
 Mean 99.98 100.25 
SD 1.111 1.359 
%RSD 1.11 1.36 
Stability of sample solution: The sample solution injected after 24 
hr did not show any appreciable change. Results are shown in 
table-6. 
Table 6: Stability data of DIC and TOL 
Drug %Assay at 0 hr %Assay at 24hr %Deviation 
DIC  99.65 101.59 1.94 
TOL 99.00 100.03 1.03 
LOD and LOQ: LOD and LOQ of DIC and TOL were determined by 
calibration curve method. Solutions of both DIC and TOL were 
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prepared in the range of 12.5-125µg/ml and 37.5-375 µg/ml 
respectively and injected in triplicate. Average peak area of three 
analyses was plotted against concentration. LOD and LOQ were 
calculated by using following equations. LOD=(3.3 ×Syx)/b, 
LOQ=(10.0×Syx)/b. Where Syx is residual variance due to 
regression; b is slope. LOD and LOQ for DIC were 1.117799 and 
3.38727 μg/ml respectively and for TOL were 3.370641 and 
10.21406 μg/ml, respectively. 
Tablet Analysis: Content of DIC and TOL found in the tablets by the 
proposed method are shown in Table-7.  
Table 7: Results of HPLC Analysis of Tablets 
Sample No Peak Area %Assay 
DIC TOL DIC TOL 
1 1536430 1439107 100.04 99.23 
2 1506312 1440512 98.08 99.33 
3 1546873 1439593 100.72 99.27 
4 1541826 1447510 100.39 99.81 
5 1531184 1436482 99.70 99.05 
6 1516676 1433833 98.75 98.87 
 AVG 99.61 99.26 
SD 1.011 0.318 
%RSD 1.02 0.32 
CONCLUSION 
RP-HPLC method was developed and validated for simultaneous 
estimation of Diclofenac and Tolperisone in tablet dosage form. The 
resolution between two peaks was always more than 2. The system 
suitability tests revealed that numbers of theoretical plates were above 
2000 and tailing factor is less than 2. DIC and TOL showed a linearity of 
response between 12.5-125µg/ml and 37.5-375 µg/ml.
 
The peak 
areas of the chromatograms were plotted against the concentration 
of DIC and TOL to obtain the calibration curve. The linearity’s were 
represented by a linear regression equation as follows: 
y(DIC)=33207.x+61482 (r2=0.999); y(TOL)=9704.x+14506 
(r2=0.999). The percentage recoveries of Diclofenac and Tolperisone are 
100.75 % and 100.84 % respectively and it shows the accuracy of method. 
The regression value is 0.999 for both DIC and TOL and the response is 
linear. Repeatability and intermediate precision values were within the 
acceptable limits. This indicates that the method is precise. Selectivity 
experiment shows that there is no interference or overlapping of the 
peaks either due to excipients or diluents with the main peak of DIC and 
TOL. The lowest values of LOD and LOQ as obtained by the proposed 
method indicate that the method is sensitive. The solution stability studies 
indicate that both the drugs were stable up to 24 hours. Change in flow 
rate, temperature and mobile phase composition doesn't cause any 
significant change in results shows stability of the development 
method.The percentage RSD for precision is <2 which confirms that 
method is sufficiently precise. The total run time required for the 
method is only 10 minutes for eluting both Diclofenac and 
Tolperisone. So, this method is fast, accurate, precise and sensitive 
hence it can be employed for routine quality control of tablets 
containing both drugs in industries. 
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